Treatment of biofilms-associated with refractory infections of skin/soft tissue and wounds remains a worldwide problem. The interactions of antimicrobial dressings/drugs with bacterial load, biofilm matrix, and overall protein-rich wound microenvironment are still not fully understood. The overall composition of the dressing or drug applied to the skin, soft tissue, or wound as well as the concentration of the active substance and the microenvironment are considered to be key factors in the topical treatment. Therefore, further research and exploration are needed for the development of anti-biofilm therapeutic strategies for skin and soft tissue infections, especially the application of active wound dressings or drugs.
Clinical medicine is currently facing a new challenge: skin and soft tissue biofilms formed by refractory and antimicrobial-resistant bacteria such as Actinomycetes, Spirochetes, Mycoplasma, Chlamydia, Rickettsia, and other microorganisms such as fungi. There is no consensus on which antimicrobial(s) to choose and how to treat the skin and soft tissue biofilms caused by resistant and refractory infectious agents. The aims of this research topic, therefore, are to gather recent development in theoretical mechanisms of biofilms in wounds, skin, and soft tissues formed by resistant and refractory infectious agents, and to congregate new technologies, new methods, and new innovations for the treatment of such biofilms.
This research topic welcomes all acceptable article types. Sub-topics could include, but are not limited to:
1. Antimicrobials that should be used to treat biofilms in wounds and skin/soft tissues caused by resistant and refractory infections.
2. New technologies and methods for the treatment of these biofilms.
3. Theoretical mechanisms on the occurrence and formation of wound and skin/soft tissue biofilms formed by resistant and refractory infectious agents.
4. Detection methods for wound biofilms and microorganisms.
5. Microbial profile dynamic after the wound or soft tissue injury.
6. Application of advanced anti-biofilm dressings, anti-biofilm drugs, and other anti-biofilm treatments.
Treatment of biofilms-associated with refractory infections of skin/soft tissue and wounds remains a worldwide problem. The interactions of antimicrobial dressings/drugs with bacterial load, biofilm matrix, and overall protein-rich wound microenvironment are still not fully understood. The overall composition of the dressing or drug applied to the skin, soft tissue, or wound as well as the concentration of the active substance and the microenvironment are considered to be key factors in the topical treatment. Therefore, further research and exploration are needed for the development of anti-biofilm therapeutic strategies for skin and soft tissue infections, especially the application of active wound dressings or drugs.
Clinical medicine is currently facing a new challenge: skin and soft tissue biofilms formed by refractory and antimicrobial-resistant bacteria such as Actinomycetes, Spirochetes, Mycoplasma, Chlamydia, Rickettsia, and other microorganisms such as fungi. There is no consensus on which antimicrobial(s) to choose and how to treat the skin and soft tissue biofilms caused by resistant and refractory infectious agents. The aims of this research topic, therefore, are to gather recent development in theoretical mechanisms of biofilms in wounds, skin, and soft tissues formed by resistant and refractory infectious agents, and to congregate new technologies, new methods, and new innovations for the treatment of such biofilms.
This research topic welcomes all acceptable article types. Sub-topics could include, but are not limited to:
1. Antimicrobials that should be used to treat biofilms in wounds and skin/soft tissues caused by resistant and refractory infections.
2. New technologies and methods for the treatment of these biofilms.
3. Theoretical mechanisms on the occurrence and formation of wound and skin/soft tissue biofilms formed by resistant and refractory infectious agents.
4. Detection methods for wound biofilms and microorganisms.
5. Microbial profile dynamic after the wound or soft tissue injury.
6. Application of advanced anti-biofilm dressings, anti-biofilm drugs, and other anti-biofilm treatments.